Syschem India reported a robust fiscal year for 2025-26, with revenue climbing 69.5% to Rs 654.63 crore and net profit rising to Rs 10.93 crore. Growth was primarily driven by the full-scale operation of its new manufacturing facility. Shareholders will vote on key leadership changes and material related-party transactions at the upcoming 33rd Annual General Meeting on September 30, 2026.
Syschem India Reports Strong FY26 Growth Following Capacity Expansion
Revenue grew to Rs 654.63 crore from Rs 386.23 crore; Net Profit rose to Rs 10.93 crore.
Reader Takeaway: New plant capacity is driving massive revenue growth, but upcoming AGM resolutions on related party deals bear watching.
What just happened
Syschem (India) Limited has released its financial performance for FY 2025-26, demonstrating a significant scale-up in operations. The company successfully transitioned its new manufacturing plant to full operational status, which directly contributed to a 69.5% surge in top-line revenue. Net profit after tax expanded to Rs 10.93 crore, a stark contrast to the Rs 0.46 crore reported in the prior fiscal year.
Why this matters
The financial results validate the company's recent capital expenditure strategy. The jump in basic EPS to Rs 2.50 reflects enhanced operational leverage. Investors now have a clear look at how the expanded capacity translates into bottom-line profitability, which is the primary driver for current valuation.
Corporate Governance and AGM
The 33rd Annual General Meeting, set for September 30, 2026, will be a focal point for shareholders. Key items include the appointment of M/s Bansal Vijay & Associates as statutory auditors and the re-designation of Executive Directors Mr. Ranjan Jain and Mr. Suninder Veer Singh. The re-designation proposal follows a previous attempt via postal ballot that did not succeed, indicating a contentious history that shareholders should monitor closely.
Risks to watch
A significant portion of company revenue is tied to related party transactions with Pharmacare International, Indosol Export, and JB Khokhani & Co. Furthermore, the company has extended a Rs 50 crore corporate guarantee to HDFC Bank for credit facilities availed by Pharmacare International. Investors should scrutinize whether these transactions are conducted on an arm’s-length basis to ensure shareholder interests are protected.